45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
95,908
Insurances with rates
37
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
103958918-2215111
$314,914
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$572,571
103958918-2215111
$154,594
69866-1030-05 - autologous cultured chondrocytes 1
Gross
$572,571
103958919-2215111
$314,914
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$572,571
103958919-2215111
$154,594
69866-1030-08 - autologous cultured chondrocytes 1
Gross
$572,571
102534551-2215105
$288,717
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$524,940
102534551-2215105
$141,734
71336-1001-01 - givosiran 189 mg/mL Soln
Gross
$524,940
51905029-2215107
$274,589
30237-8900-06 - sipuleucel-T - Susp
Gross
$499,253
51905029-2215107
$134,798
30237-8900-06 - sipuleucel-T - Susp
Gross
$499,253
1279402-2215105
$252,310
ipilimumab 200 mg / 40 mL Soln-IV 40 mL
Gross
$458,745
1279402-2215105
$123,861
ipilimumab 200 mg / 40 mL Soln-IV 40 mL
Gross
$458,745
106410809-2124721
$230,356
00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln
Gross
$418,829
106410809-2124721
$113,084
00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln
Gross
$418,829
1286149-2215105
$206,702
pegloticase 8 mg/1 mL Soln-IV
Gross
$375,822
1286149-2215105
$101,472
pegloticase 8 mg/1 mL Soln-IV
Gross
$375,822
95367892-2215105
$206,702
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$375,822
95367892-2215105
$101,472
60809-0801-01 - pegloticase 8 mg/mL Soln
Gross
$375,822
1282361-2215105
$189,060
57665-0002-02 - pegaspargase 3750. Soln
Gross
$343,745
1282361-2215105
$92,811
57665-0002-02 - pegaspargase 3750. Soln
Gross
$343,745
1282362-2215105
$189,060
54482-0301-01 - pegaspargase 3750. Soln
Gross
$343,745
1282362-2215105
$92,811
54482-0301-01 - pegaspargase 3750. Soln
Gross
$343,745
99090561-2215105
$189,060
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$343,745
99090561-2215105
$92,811
72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5
Gross
$343,745
94990000-2215105
$182,858
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$332,470
94990000-2215105
$89,767
57894-0061-03 - ustekinumab 90 mg/mL Soln
Gross
$332,470
102525788-2215105
$173,832
25682-0028-01 - ravulizumab 100 mg/mL Soln
Gross
$316,059
102525788-2215105
$85,336
25682-0028-01 - ravulizumab 100 mg/mL Soln
Gross
$316,059
96694815-2215105
$145,741
ocrelizumab 300 mg/10 mL Soln-IV
Gross
$264,984
96694815-2215105
$71,546
ocrelizumab 300 mg/10 mL Soln-IV
Gross
$264,984
105646369-2215105
$134,338
00078-0734-61 - canakinumab 150 mg/mL Soln
Gross
$244,250
105646369-2215105
$65,948
00078-0734-61 - canakinumab 150 mg/mL Soln
Gross
$244,250
95380079-2168371
$126,849
00169-7208-01 - coagulation factor VIIa 8000 mcg (
Gross
$230,634
95380079-2168371
$62,271
00169-7208-01 - coagulation factor VIIa 8000 mcg (
Gross
$230,634
100575164-2215105
$121,362
tildrakizumab-asmn 100 mg/mL Soln-Inj 1 mL
Gross
$220,659
100575164-2215105
$59,578
tildrakizumab-asmn 100 mg/mL Soln-Inj 1 mL
Gross
$220,659
101891901-2215107
$119,864
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$217,934
101891901-2215107
$58,842
72187-0401-01 - tagraxofusp 1000 mcg/mL Soln
Gross
$217,934
99247005-2215105
$117,693
75987-0130-15 - teprotumumab trbw 500 mg Powder
Gross
$213,987
99247005-2215105
$57,777
75987-0130-15 - teprotumumab trbw 500 mg Powder
Gross
$213,987
1279159-2215106
$115,115
63004-7731-01 - corticotropin 400. Soln
Gross
$209,300
1279159-2215106
$56,511
63004-7731-01 - corticotropin 400. Soln
Gross
$209,300
95048080-2215105
$109,325
47783-0101-01 - ecallantide 10 mg/mL Soln
Gross
$198,772
95048080-2215105
$53,669
47783-0101-01 - ecallantide 10 mg/mL Soln
Gross
$198,772
101883920-2215107
$101,978
79952-0110-01 - loncastuximab tesirine 10 mg Injec
Gross
$185,415
101883920-2215107
$50,062
79952-0110-01 - loncastuximab tesirine 10 mg Injec
Gross
$185,415
1287035-2215107
$95,047
76128-0155-75 - porfimer 75. mg REC Injection
Gross
$172,812
1287035-2215107
$46,659
76128-0155-75 - porfimer 75. mg REC Injection
Gross
$172,812
102917747-2215107
$91,780
72493-0103-03 - mitoMYcin 40 mg Kit
Gross
$166,874
102917747-2215107
$45,056
72493-0103-03 - mitoMYcin 40 mg Kit
Gross
$166,874
1287179-2215105
$91,429
57894-0060-03 - ustekinumab Soln
Gross
$166,235
1287179-2215105
$44,883
57894-0060-03 - ustekinumab Soln
Gross
$166,235
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 103958918-2215111 | 69866-1030-05 - autologous cultured chondrocytes 1 | $572,571 | $314,914 | — | — | 4 |
| 103958918-2215111 | 69866-1030-05 - autologous cultured chondrocytes 1 | $572,571 | $154,594 | — | — | 9 |
| 103958919-2215111 | 69866-1030-08 - autologous cultured chondrocytes 1 | $572,571 | $314,914 | — | — | 4 |
| 103958919-2215111 | 69866-1030-08 - autologous cultured chondrocytes 1 | $572,571 | $154,594 | — | — | 9 |
| 102534551-2215105 | 71336-1001-01 - givosiran 189 mg/mL Soln | $524,940 | $288,717 | — | — | 4 |
| 102534551-2215105 | 71336-1001-01 - givosiran 189 mg/mL Soln | $524,940 | $141,734 | — | — | 9 |
| 51905029-2215107 | 30237-8900-06 - sipuleucel-T - Susp | $499,253 | $274,589 | — | — | 4 |
| 51905029-2215107 | 30237-8900-06 - sipuleucel-T - Susp | $499,253 | $134,798 | — | — | 9 |
| 1279402-2215105 | ipilimumab 200 mg / 40 mL Soln-IV 40 mL | $458,745 | $252,310 | — | — | 4 |
| 1279402-2215105 | ipilimumab 200 mg / 40 mL Soln-IV 40 mL | $458,745 | $123,861 | — | — | 9 |
| 106410809-2124721 | 00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln | $418,829 | $230,356 | — | — | 4 |
| 106410809-2124721 | 00310-3040-00 - anifrolumab fnia 300 mg/2 mL Soln | $418,829 | $113,084 | — | — | 9 |
| 1286149-2215105 | pegloticase 8 mg/1 mL Soln-IV | $375,822 | $206,702 | — | — | 4 |
| 1286149-2215105 | pegloticase 8 mg/1 mL Soln-IV | $375,822 | $101,472 | — | — | 9 |
| 95367892-2215105 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $375,822 | $206,702 | — | — | 4 |
| 95367892-2215105 | 60809-0801-01 - pegloticase 8 mg/mL Soln | $375,822 | $101,472 | — | — | 9 |
| 1282361-2215105 | 57665-0002-02 - pegaspargase 3750. Soln | $343,745 | $189,060 | — | — | 4 |
| 1282361-2215105 | 57665-0002-02 - pegaspargase 3750. Soln | $343,745 | $92,811 | — | — | 9 |
| 1282362-2215105 | 54482-0301-01 - pegaspargase 3750. Soln | $343,745 | $189,060 | — | — | 4 |
| 1282362-2215105 | 54482-0301-01 - pegaspargase 3750. Soln | $343,745 | $92,811 | — | — | 9 |
| 99090561-2215105 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $343,745 | $189,060 | — | — | 4 |
| 99090561-2215105 | 72694-0954-01 - pegaspargase 3,750 IntlUnit(s) / 5 | $343,745 | $92,811 | — | — | 9 |
| 94990000-2215105 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $332,470 | $182,858 | — | — | 4 |
| 94990000-2215105 | 57894-0061-03 - ustekinumab 90 mg/mL Soln | $332,470 | $89,767 | — | — | 9 |
| 102525788-2215105 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $316,059 | $173,832 | — | — | 4 |
| 102525788-2215105 | 25682-0028-01 - ravulizumab 100 mg/mL Soln | $316,059 | $85,336 | — | — | 14 |
| 96694815-2215105 | ocrelizumab 300 mg/10 mL Soln-IV | $264,984 | $145,741 | — | — | 4 |
| 96694815-2215105 | ocrelizumab 300 mg/10 mL Soln-IV | $264,984 | $71,546 | — | — | 14 |
| 105646369-2215105 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $244,250 | $134,338 | — | — | 4 |
| 105646369-2215105 | 00078-0734-61 - canakinumab 150 mg/mL Soln | $244,250 | $65,948 | — | — | 9 |
| 95380079-2168371 | 00169-7208-01 - coagulation factor VIIa 8000 mcg ( | $230,634 | $126,849 | — | — | 4 |
| 95380079-2168371 | 00169-7208-01 - coagulation factor VIIa 8000 mcg ( | $230,634 | $62,271 | — | — | 9 |
| 100575164-2215105 | tildrakizumab-asmn 100 mg/mL Soln-Inj 1 mL | $220,659 | $121,362 | — | — | 4 |
| 100575164-2215105 | tildrakizumab-asmn 100 mg/mL Soln-Inj 1 mL | $220,659 | $59,578 | — | — | 9 |
| 101891901-2215107 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $217,934 | $119,864 | — | — | 4 |
| 101891901-2215107 | 72187-0401-01 - tagraxofusp 1000 mcg/mL Soln | $217,934 | $58,842 | — | — | 9 |
| 99247005-2215105 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $213,987 | $117,693 | — | — | 4 |
| 99247005-2215105 | 75987-0130-15 - teprotumumab trbw 500 mg Powder | $213,987 | $57,777 | — | — | 9 |
| 1279159-2215106 | 63004-7731-01 - corticotropin 400. Soln | $209,300 | $115,115 | — | — | 4 |
| 1279159-2215106 | 63004-7731-01 - corticotropin 400. Soln | $209,300 | $56,511 | — | — | 9 |
| 95048080-2215105 | 47783-0101-01 - ecallantide 10 mg/mL Soln | $198,772 | $109,325 | — | — | 4 |
| 95048080-2215105 | 47783-0101-01 - ecallantide 10 mg/mL Soln | $198,772 | $53,669 | — | — | 9 |
| 101883920-2215107 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $185,415 | $101,978 | — | — | 4 |
| 101883920-2215107 | 79952-0110-01 - loncastuximab tesirine 10 mg Injec | $185,415 | $50,062 | — | — | 9 |
| 1287035-2215107 | 76128-0155-75 - porfimer 75. mg REC Injection | $172,812 | $95,047 | — | — | 4 |
| 1287035-2215107 | 76128-0155-75 - porfimer 75. mg REC Injection | $172,812 | $46,659 | — | — | 14 |
| 102917747-2215107 | 72493-0103-03 - mitoMYcin 40 mg Kit | $166,874 | $91,780 | — | — | 4 |
| 102917747-2215107 | 72493-0103-03 - mitoMYcin 40 mg Kit | $166,874 | $45,056 | — | — | 9 |
| 1287179-2215105 | 57894-0060-03 - ustekinumab Soln | $166,235 | $91,429 | — | — | 4 |
| 1287179-2215105 | 57894-0060-03 - ustekinumab Soln | $166,235 | $44,883 | — | — | 9 |
Showing top 50 of 95,908 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.